AVANAFIL, NEW DRUG FOR ERECTILE DYSFUNCTION, FDA APRIL 2012

Avanafil is a PDE5 inhibitor approved for erectile dysfunction on April 27, 2012.^[1] Avanafil is known by the trademark name Stendra and was developed by Vivus Inc. It acts by inhibiting a specific phosphodiesterase type 5 enzyme which is found in various body tissues, but primarily in the corpus cavernosum penis, as well as the retina. Other similar drugs are sildenafil, tadalafil and vardenafil. The advantage of avanafil is that it has very fast onset of action compared with other PDE5 inhibitors.

CAS number 330784-47-9
Synthesis Avanafil can be synthesized from a benzylamine derivative and a pyrimidine derivative:[2] “FDA approves Stendra for erectile dysfunction” (Press release). Food and Drug Administration (FDA). April 27, 2012. Yamada, K.; Matsuki, K.; Omori, K.; Kikkawa, K.; 2004, U.S. Patent 6,797,709